How recognizing the unique characteristics of each patient optimizes resources and maximizes impact Medication non-adherence is an age-old problem that pharmaceutical companies have been grappling with for decades. According to industry research, the global pharmaceutical industry loses…
Read more
AllazoHealth CEO Clifford Jones and Chief Operating Officer William Grambley recently answered questions about patient intervention data: what it is, how clients employ it, and how AllazoHealth uses this data to accurately predict individual patient…
Read more
We live in exciting times for adherence, and the pharma industry is playing a critical role, according to Mark Degatano, a pharmaceutical industry analytics expert who is on the advisory board of AllazoHealth. Degatano’s expertise…
Read more
With medication non-adherence costing the industry more than $600 billion a year, many pharmaceutical companies are creating medication adherence programs, often in conjunction with pharmacists and payers. According to Andrea Kasprzyk, Director of Sales at…
Read more
What do payers consider as they grapple with the medication access and adherence needs of at-risk patients during the Covid-19 pandemic? Experts at McMann Managed Markets and Syneos Health surveyed their proprietary payer advisory boards…
Read more
Pharmacies can use artificial intelligence to make adherence improvements that meet the goals of their payer contracts, specifically the ones known as DIR (direct and indirect remuneration). When it comes to getting reimbursements, adherence plays…
Read more